News

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Mixture-of-recursions delivers 2x faster inference—Here’s how to implement it
Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without ...
Top 2 Health Care Stocks You May Want To Dump This Quarter
As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as ...
Regulatory Green Lights Are Powering the Next Phase of the AI Health Boom
Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova’s future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at ...
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, ...
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is ...
Recursion Pharmaceuticals Stock Gains on Plans to Buy Drug-Development Interest from Rallybio
Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...
Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio
Investing.com -- Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock surged 11.5% while Rallybio Corp (NASDAQ: RLYB) shares jumped 35% Monday after Recursion acquired full rights to REV102, an oral ...
Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug
Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.